Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of NALDEBAIN ER vs Nalbuphine in Healthy Volunteers
NCT04256434Phase 1Completed
- Sponsor
- Lumosa Therapeutics
- Start
- Jan 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dinalbuphine sebacate in postoperative pain (2 arms), sponsored by Lumosa Therapeutics. Primary endpoint: Bioavailability of nalbuphine. Started Jan 2020; status: completed.
02
Drugs
dinalbuphine sebacate
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04256434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04256434.